Ophthalmology Times

An Egyptian research team led by Aya Refaat Ali Mohammed, MD, reported that multifocal electroretinography (mfERG) was valuable for demonstrating the effect of one dose of the intravitreal dexamethasone implant (Ozurdex, Allergan). Mohammed is a resident in ophthalmology at Minia Health Insurance Hospital, Minya, Egypt. She was joined in this study by clinicians from the Faculty of Medicine, Minia University, Minya. The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects of one intravitreal dexamethasone implant in eyes with refractory diabetic macular edema based on optical coherence tomography images, the best-corrected logarithm of the minimum angle of resolution visual acuity (logMAR BCVA), and mfERGs. Read More: https://hubs.li/Q03dKQkQ0

Character Biosciences announced it has secured a $93 million Series B financing round for the advancement of its pipeline to treat degenerative eye diseases such as age-related macular degeneration (AMD). Funding was co-led by new investors aMoon and Luma Group, with additional participation from Bausch + Lomb and Jefferson Life Sciences. Existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures also contributed. Read More: https://hubs.li/Q03dL7JM0

Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. This announcement comes on the heels of recent news that Alcon intends to acquire LENSAR, which is anticipated to close in mid-to-late 2025. According to a press release from Alcon, Aurion will operate as a separate company with “full support,” including “broader R&D, regulatory, medical ophthalmic, and commercial capabilities” the company has at its disposal. Read More: https://hubs.li/Q03dKQMP0

Nanoscope Therapeutics announced the publication of clinical data on vision restoration in retinitis pigmentosa (RP) in a paper titled “A synthetic opsin restores vision in patients with severe retinal degeneration” in Molecular Therapy. In the paper Nanoscope described Multi-Characteristic Opsin (MCO-010), a synthetic opsin with broad spectral sensitivity. Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells. According to the paper, in preclinical trials, Synthopsin-MCO-010 was shown to restore the visual behavior in RP mouse models. For the study, the synthopsin was packaged into an optimized AAV2 gene therapy vector that targets human retinal bipolar cells Read More: https://hubs.li/Q03dL4Pn0

Join Dr. Michael Klufas virtually on April 3 for an expert-led, case-based discussion on the latest therapies for nAMD and DME. Key Insights: ?? Real-world efficacy and durability of new treatments ?? Impact of enhanced retinal drying on injection frequency and burden ?? Practical applications to optimize patient care Secure your spot now. Register today! https://hubs.li/Q03dWdf50

Bausch + Lomb has announced a voluntary recall of intraocular lenses (IOLs) from its enVista platform, an action taken out of an abundance of caution after the company received reports of complications. The cause of said complications could not be immediately explained, according to a news release. Read More: https://hubs.li/Q03dKS1m0

Sponsored by Bausch + Lomb. Precision in Focus with the Osher Magnifier HD ?? The advanced double-hinged design of the Osher Magnifier HD offers enhanced positioning flexibility and precise control for viewing delicate instrument tips, allowing for meticulous detail and helping surgeons achieve optimal outcomes. See the difference in every procedure. Learn more at https://hubs.li/Q03dL6x70 #Ad #BauschSurgical #Ophthalmology #Storz #OsherMagnifier

?? Sightlines Newsletter: Key Industry Updates ?? ?? Alcon Expands Its Reach – Acquires a majority stake in Aurion Biotech, plans to acquire LENSAR, and secures CE Mark approval for Clareon Vivity. ?? Opthea’s Phase 3 Trial Falls Short – Wet AMD trial fails to meet its primary endpoint, raising financial concerns. ?? Bausch + Lomb Recalls enVista IOLs – Voluntary recall due to safety concerns, plus new Phase 4 dry eye study results. ?? Ocugen Advances OCU200 Trial – Second cohort dosing approved in its Phase 1 study for diabetic macular edema.

Unity Biotechnology announced topline results from its phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. Results from the trial include data from all patients through 24 weeks and the majority of patients through 36 weeks. Read More: https://hubs.li/Q03dl3zt0

In the final episode of our series on retinal disease treatment, Aleksandra Rachitskaya, MD, and Jordan Graff, MD, FACS, cover how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action. Click here to watch now: https://ow.ly/zre650Vf2TO #portdeliverysystem #retinaldiseases